Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

There’s no “silver bullet” for this problem, which is largely driven by clinical inertia, but some efforts are chipping away ...

Thanks, Andrew. I'll start with CK-586, our next cardiac myosin inhibitor for the potential treatment of a subset of patients with heart failure with preserved ejection fraction or HFpEF ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q3 2024 earnings call. [Operator ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

RAAS inhibition has no known prognostic benefit in heart failure with preserved ejection fraction. Efforts should be made to initiate, titrate and maintain patients with HFrEF on RAAS inhibitor ...

Normally, the ejection fraction should be between 55 ... system provides greater insight as to what medical interventions should be implemented at which stages. The treatment of congestive heart ...

BACKGROUND: The ability to predict recovery of left ventricular ejection fraction (LVEF) in response to guideline-directed therapy among patients with nonischemic cardiomyopathy is desired. We sought ...

NYHA class was more likely to have improved at 1 year in the treatment ... EF = ejection fraction; HF = heart failure; HR = hazard ratio; I-PRESERVE = irbesartan in heart failure with preserved ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

EF = ejection fraction; HF = heart failure; HR = hazard ratio; I-PRESERVE = irbesartan in heart failure with preserved systolic function; LV = left ventricular; MI = myocardial infarction ...